SAN ANTONIO, Aug. 21, 2013 /PRNewswire/ -- Urocit®-K (extended release potassium citrate), the proven urological treatment that blazed a trail into space to help NASA astronauts combat kidney stones, has begun a new journey here on Earth.
With the Urocit-K flagship leading the way, Mission Pharmacal Company has launched a new sales force to better deliver its entire fleet of urology medicines into the hands of physicians nationwide.
Together with Urocit-K, Lithostat® (acetohydroxamic acid) and Thiola® (tiopronin) offer relief to people suffering from several types of kidney stones. A fourth Mission urology drug, Uribel®, (methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, hyoscyamine sulfate) treats urinary tract infections. These drugs, considered among the leaders in their class, represent a sizable percentage of Mission's overall sales.
Brian Card, Executive Director of Women's Health and Urology sales for Mission Pharmacal, said this new sales force is equipped to capitalize on the company's 30 years of pioneering experience in the field of kidney stone disease therapy.
"This expansion gives us an opportunity to re-establish our dedication to the field of urology," Card said. "Mission has led the way in the treatment of kidney stones and actually pioneered the tests that are still used today to diagnose kidney stone etiology."
Based in San Antonio, Mission Pharmacal at one time had a specialty sales team dedicated to urology products. In recent years, though, one team promoted both women's health products and urological products.
This summer, Mission split that sales force, hired additional sales reps and dedicated about 30 sales representatives to urology products alone. The new teams will cover the country's major markets, Card said.
The sales representatives are employed by Alamo
|SOURCE Mission Pharmacal Company|
Copyright©2012 PR Newswire.
All rights reserved